Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.64 USD | -8.30% | -15.94% | +8.67% |
Apr. 05 | Bristol-Myers Squibb, 2seventy Bio Say FDA Approves Expansion of Myeloma Treatment's Indication | MT |
Apr. 05 | Bristol Myers, 2seventy Get FDA OK for Earlier Abecma Use in Multiple Myeloma | DJ |
Financials (USD)
Sales 2024 * | 87.65M | Sales 2025 * | 114M | Capitalization | 238M |
---|---|---|---|---|---|
Net income 2024 * | -97M | Net income 2025 * | -32M | EV / Sales 2024 * | 2.72 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.09 x |
P/E ratio 2024 * |
-2.23
x | P/E ratio 2025 * |
-6.72
x | Employees | 274 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.5% |
Latest transcript on 2seventy bio, Inc.
1 day | -8.30% | ||
1 week | -15.94% | ||
Current month | -13.27% | ||
1 month | +10.74% | ||
3 months | +44.55% | ||
6 months | +16.00% | ||
Current year | +8.67% |
Managers | Title | Age | Since |
---|---|---|---|
Chip Baird
CEO | Chief Executive Officer | 52 | - |
Nick Leschly
CHM | Chairman | 51 | 21-05-03 |
Susan Abu-Absi
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Daniel Lynch
BRD | Director/Board Member | 66 | 21-10-14 |
Nick Leschly
CHM | Chairman | 51 | 21-05-03 |
Chip Baird
CEO | Chief Executive Officer | 52 | - |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
2.23% | 2 M€ | -25.75% | ||
0.03% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-18 | 4.64 | -8.30% | 714,023 |
24-04-17 | 5.06 | +4.12% | 896,008 |
24-04-16 | 4.86 | -2.51% | 932,484 |
24-04-15 | 4.985 | -1.09% | 393,377 |
24-04-12 | 5.04 | -8.70% | 797,617 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.67% | 238M | |
-1.82% | 41.35B | |
+44.25% | 40.38B | |
+2.56% | 39.05B | |
-12.11% | 26.67B | |
+3.09% | 24.07B | |
-24.16% | 18.36B | |
+22.12% | 11.6B | |
-3.74% | 11.68B | |
+7.75% | 11.15B |
- Stock Market
- Equities
- TSVT Stock